Literature DB >> 17609825

Hepatic resection for colorectal liver metastases.

W Y Lau1, E C H Lai.   

Abstract

INTRODUCTION: Nearly 50 percent of patients who have colorectal carcinoma will develop liver metastases, which is frequently the cause of death. Liver resection is the only curative treatment for patients with colorectal metastases confined to the liver. However, liver resection can be performed in only ten percent of patients. A strategy to improve resectability and outcome of patients with colorectal liver metastases is needed.
METHODS: The progress and outcome of patients, who had colorectal liver metastases and underwent liver resection in a tertiary surgical centre between January 1998 and December 2002, were retrospectively studied.
RESULTS: During the five-year study period, 42 patients with colorectal liver metastasis underwent hepatic resection. 36 patients received primary liver resection. Six patients with initially unresectable disease received salvage surgery after tumour downstaging with systemic chemotherapy. Five of the 42 patients needed repeat liver resection for recurrent colorectal liver metastases. The hospital mortality rate was 2.1 percent. 11.9 percent of patients had major postoperative complications. The median survival was 49 months. The one-, three- and five-year overall survival rates after resection were 91 percent, 54 percent, and 37 percent, respectively; and the recurrence rate was 76 percent. The five-year survival rate with salvage surgery after tumour downstaging was 34 percent, and the corresponding figure, after repeat liver resection, for recurrent liver metastases was 27 percent.
CONCLUSION: Hepatic resection for colorectal metastases confined to the liver resulted in reasonably good long-term survival, with acceptably low operative mortality and morbidity. Our results were compatible with the international standard of liver resection for colorectal liver metastases.

Entities:  

Mesh:

Year:  2007        PMID: 17609825

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  7 in total

Review 1.  Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer.

Authors:  Jianmin Xu; Xinyu Qin; Jianping Wang; Suzhan Zhang; Yunshi Zhong; Li Ren; Ye Wei; Shaochong Zeng; Deseng Wan; Shu Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-28       Impact factor: 4.553

2.  Conventional laparoscopic and robot-assisted laparoscopic liver resection for benign and malignant pathologies: a cohort study.

Authors:  Eric C H Lai; Chung Ngai Tang; Michael K W Li
Journal:  J Robot Surg       Date:  2011-09-18

3.  Successful combination therapy of radical liver resection with 5-fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: report of a case.

Authors:  Takanori Ochiai; Taiki Masuda; Masayuki Yagi; Reo Kasai; Takaki Furuyama; Kanako Tsukamoto; Hiromitsu Ito; Kimihiro Igari; Arihiro Aihara; Yoichi Kumagai; Michio Iida; Hajime Odajima; Shinji Tanaka; Shigeki Arii; Shigeru Yamazaki
Journal:  Int Surg       Date:  2012 Jan-Mar

4.  Targeting the angiotensin II type 2 receptor (AT2R) in colorectal liver metastases.

Authors:  Eleanor I Ager; Way W Chong; Shu-Wen Wen; Christopher Christophi
Journal:  Cancer Cell Int       Date:  2010-06-28       Impact factor: 5.722

5.  Impact of liver tumor percutaneous radiofrequency ablation on circulating tumor cells.

Authors:  Yang Li; Na Huang; Chunlin Wang; Huanrong Ma; Minyu Zhou; Li Lin; Zhenhua Huang; Li Sun; Min Shi; Wangjun Liao
Journal:  Oncol Lett       Date:  2018-06-25       Impact factor: 2.967

6.  Differential analysis revealing APOC1 to be a diagnostic and prognostic marker for liver metastases of colorectal cancer.

Authors:  Hai-Yu Shen; Fang-Ze Wei; Qian Liu
Journal:  World J Clin Cases       Date:  2021-06-06       Impact factor: 1.337

7.  Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors.

Authors:  Gena P Kanas; Aliki Taylor; John N Primrose; Wendy J Langeberg; Michael A Kelsh; Fionna S Mowat; Dominik D Alexander; Michael A Choti; Graeme Poston
Journal:  Clin Epidemiol       Date:  2012-11-07       Impact factor: 4.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.